The combination of amlodipine and angiotensin receptor blocker or diuretics in high-risk hypertensive patients: Rationale, design and baseline characteristics

Journal of Human Hypertension

Volumn 25, Issue 4, 2011, Pages 271-277

  Wang, W ^a   Ma, L ^a   Zhang, Y ^a   Deng, Q ^a   Liu, M ^a   Liu, L ^a,b  

^a FUWAI HOSPITAL   (China)

^b Beijing Hypertension League Institute   (China)

Author keywords

amlodipine; angiotensin II receptor blocker; antihypertensive therapy; diuretics; high risk

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SIMVASTATIN; TELMISARTAN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DYSLIPIDEMIA; FEMALE; HEART DEATH; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; KIDNEY DISEASE; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SMOKING; STABLE ANGINA PECTORIS; STROKE; SYSTOLIC BLOOD PRESSURE; TRANSIENT ISCHEMIC ATTACK;

AGED; AMILORIDE; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; CHINA; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79952819391     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2010.45     Document Type: Article

References (30)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365(9455): 217-223. (Pubitemid 40138015)
2. Bramlage P. Fixed combination of irbesartan and hydro-chlorothiazide in the management of hypertension. Vascular Health and Risk Management 2009; 5: 213-224.
3. Wang L. 2002 National Nutrition and Health Survey: Report I [in Chinese], General Report. People's Medical Publishing House: Beijing, 2005.
4. Annals of Health of China Committee. 1999 Annals of Health of China [in Chinese]. People's Health Press: Beijing, China, 2000.
5. Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular disease in the Asia Pacific Region. J Hypertens 2003; 21: 707-716.
6. The ALLHAT Officers Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angio-tensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
7. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358: 1305-1315. (Pubitemid 33016494)
8. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. Joint national committee on prevention, detection, evaluation, treatment of high blood pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
9. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. Management of arterial hypertension of the European society of hypertension; European society of cardiologypar. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). J Hypertens 2007; 25: 1105-1187. (Pubitemid 46924065)
10. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiolo-gical studies. Br Med J 2009; 338: b1665.
11. Wang JG, Staessen JA, Gong L, Liu L. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Int Med 2000; 160(2): 211-220 (Pubitemid 30054341)
12. Gong L, Zhang W, Zhu Y, Zhu J, Kong D, Page V et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996; 14(10): 1237-1245. (Pubitemid 26343504)
13. Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A, FEVER Study Group. The Felodipine Event Reduction (FEVER) study: A randomized long-term placebo controlled trial in Chinese hypertensive patients. J Hypertens 2005; 23: 2157-2172. (Pubitemid 41666745)
14. Hashimoto J, Hirayama H, Hanasawa T, Watabe D, Asayama K, Metoki H et al. Efficacy of combination antihypertensive therapy with low-dose indapamide: assessment by blood pressure self-monitoring at home. Clin Exp Hypertens 2005; 27(4): 331-341. (Pubitemid 40686599)
15. Littlejohn 3rd TW, Majul CR, Olvera R, Seeber M, Kobe M, Guthrie R et al. Study investigators. Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4x4 factorial study. Postgrad Med 2009; 121(2): 5-14.
16. Sever P, Dahlof B, Poulter N, Wedel H, Beevers G, Caulfield M et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac outcomes trial. Eur Heart J 2006; 27(24): 2982-2988. (Pubitemid 44950442)
17. Kyvelou SM, Vyssoulis GP, Karpanou EA, Adamopoulos DN, Zervoudaki AI, Pietri PG et al. Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid profile: an open multi-drug comparison trial. Hellenic J Cardiol 2006; 47: 21-28.
18. Sever PS, Poulter NR, Dahlof B, Wedel H, ASCOT Investigators. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension. J Hypertens 2009; 27(5): 947-954.
19. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hyperch-olesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288(23): 2998-3007.
20. Chinese Guidelines for Prevention Treatment of Hypertension (Revised Edition 2005). Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension. People's Medical Publishing House, 2005.
21. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462-1536.
22. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. Br Med J 2004; 328: 634-640. (Pubitemid 38340037)
23. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur Heart J 2003; 24: 1601-1610. (Pubitemid 37012194)
24. Weber MA, Bakris GL, Dahlöf B, Pitt B, Velazquez E, Gupte J et al. Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Pressure 2007; 16(1): 13-19. (Pubitemid 46672249)
25. Jamerson KA, Bakris GL, Wun CC, Dahlöf B, Lefkowitz M, Manfreda S et al. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens 2004; 17(9): 793-801. (Pubitemid 39201095)
26. Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004; 148(1): 52-61. (Pubitemid 38906646)
27. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. JHypertens 2001; 19(6): 1139-1147. (Pubitemid 32493649)
28. Ogihara T, Saruta T, Rakugi H, Shimamoto K, Ito S, Matsuoka H et al. Rationale, study design and implementation of the COLM study: the combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients. Hypertens Res 2009; 32(2): 163-167.
29. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs 2004; 64(Suppl 2): 43-60. (Pubitemid 39657106)
30. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D et al. For the DASH-Sodium Collaborative Research Group: Effects on blood pressure of reduced dietary sodium the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001; 344: 3-10. (Pubitemid 32064838)